Zentalis Pharmaceuticals (ZNTL)
NASDAQ:ZNTL
Total Valuation
Zentalis Pharmaceuticals has a market cap or net worth of $195.77M. The enterprise value is $199.35M.
Market Cap$195.77M
Enterprise Value$199.35M
Share Statistics
Zentalis Pharmaceuticals has 70,931,015 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding70,931,015
Owned by Insiders29.49%
Owned by Institutions18.34%
Financial Efficiency
Zentalis Pharmaceuticals’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -57.07%.
Return on Equity (ROE)-0.63
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-57.07%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee0.00
Profits Per Employee-825.66K
Employee Count166
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Zentalis Pharmaceuticals is ―. Zentalis Pharmaceuticals’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio0.45
Price to Fair Value0.45
Price to FCF-0.77
Price to Operating Cash Flow-1.53
PEG Ratio0.04
Income Statement
In the last 12 months, Zentalis Pharmaceuticals had revenue of 0.00 and earned -137.06M in profits. Earnings per share was -1.91.
Revenue0.00
Gross Profit-739.00K
Operating Income-146.25M
Pretax Income-136.62M
Net Income-137.06M
EBITDA-145.51M
Earnings Per Share (EPS)-1.91
Cash Flow
In the last 12 months, operating cash flow was -125.25M and capital expenditures 0.00, giving a free cash flow of -125.25M billion.
Operating Cash Flow-125.25M
Free Cash Flow-125.25M
Free Cash Flow per Share-1.77
Dividends & Yields
Zentalis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.68
52-Week Price Change135.90%
50-Day Moving Average2.52
200-Day Moving Average1.84
Relative Strength Index (RSI)56.54
Average Volume (3m)716.92K
Important Dates
Zentalis Pharmaceuticals upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Zentalis Pharmaceuticals as a current ratio of 6.93, with Debt / Equity ratio of 18.31%
Current Ratio6.93
Quick Ratio6.93
Debt to Market Cap0.04
Net Debt to EBITDA-0.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Zentalis Pharmaceuticals has paid 442.00K in taxes.
Income Tax442.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Zentalis Pharmaceuticals EV to EBITDA ratio is -0.69, with an EV/FCF ratio of -0.80.
EV to Sales0.00
EV to EBITDA-0.69
EV to Free Cash Flow-0.80
EV to Operating Cash Flow-0.80
Balance Sheet
Zentalis Pharmaceuticals has $245.89M in cash and marketable securities with $39.58M in debt, giving a net cash position of $206.32M billion.
Cash & Marketable Securities$245.89M
Total Debt$39.58M
Net Cash$206.32M
Net Cash Per Share$2.91
Tangible Book Value Per Share$3.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Zentalis Pharmaceuticals is $7.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.25
Price Target Upside414.18% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-33.76%
EPS Growth Forecast17.54%